Table 4. studies of IORT in locally recurrent colorectal cancers.
| Author/Year | Sample size | Study design | IORT type | IORT dose (Gy) | Prior EBRT % | Adj. EBRT % | Median Follow up | LC 5year (%) | OS 5year (%) | Toxicity grade 3 or > |
|---|---|---|---|---|---|---|---|---|---|---|
| Suzuki et al. [63] 1995 | 106 Sx+IORT:42 Sx:64 |
NRC | IOERT | 10–30 | 25 | 98 | 44 | Sx+IORT:60% Sx:7% at 3years |
Sx+IORT:19 Sx: 7% P=0.0006 |
Total-36% Abcess-5 GI/GU-9 wound-3 |
| Valentini et al. [66] 1999 | 47 Sx+IORT:11 Sx:14 |
NRC | IOERT | 10–15 | 28 | 100 | 80 | Sx+IORT:80 Sx:24 p < 0.05 |
Sx+IORT:41 Sx:16 N.S diff |
Hydronephrosis-1 Neuropathy-0* |
| Alektiar et al. [75] 2000 | 74 | RC | HDR-IORT | 10–18 | 53 | 39 | 22 |
R0+IORT- 43 R(+) +IORT-26 p = 0.02 |
R0+IORT-36 R(+) +IORT-11 p = 0.04 |
Fistula-8* Neuropathy-1* Ureter-10* Wound-5* |
| Lindel et al. [76] 2001 | IORT-49 No IORT-20 |
NRC | IOERT | 10–20 | 14 | 94 | NR |
R0 + IORT-56 R(+) +IORT-14 |
R0 + IORT-40 R(+)+IORT-17 |
Wound complication-4* Neuropathy-4* |
| Wiig et al. [67] 2002 | 107 Sx+IORT:59 Sx:48 |
NRC | IOERT | 15–20 | 0 | 100 | NR | Sx+IORT:50 Sx: 30 N.S diff |
Sx+IORT:30 Sx: 30% N.S diff |
late toxicity: NR Acute complication: N.s diff |
| Dresen et al [69]. 2008 | 147 | RC | IOERT | 10.–17.5 | 53 | 84 | NR |
R0 + IORT-69 R1 + IORT-29 R2 + IORT-28 p < 0.001(3yr) |
R0 + IORT-59 R1 + IORT-27 R2 + IORT-24 p < 0.001(3yr) |
Neuropathy-16* Ureter stenosis-4* |
| Haddock et al. [65] 2011 | 607 | PC | IOERT | 7.5–30 | 45 | 96 | 44 |
R0 + IORT-79 R1 + IORT-56 R2 + IORT-49 p < 0.001 |
R0 + IORT-46 R1 + IORT-27 R2 + IORT-16 p< 0.001 |
Total-11% Wound-42* Neropathy-18* |
| Roeder et al.[70] 2012 | 97 | PC | IOERT | 10–20 | 44 | 52 | 33 |
R0 + IORT-82 R1 + IORT-41 R2 + IORT-18 p < 0.001(3yr) |
R0 + IORT-80 R1 + IORT-37 R2 + IORT-35 p < 0.001(3yr) |
Acute: Abscess /fistula-16 Late: Neuropathy-8* Ureter stenosis-3* |
| Calvo et al. [68] 2013 | 60 | RC | IOERT | 10–15 | 50 | 47 | 36 | 44 R0 vs R1: HR-2.09, p = 0.05 |
43 R0 vs R1:HR-2.9, p = 0.05 |
Total:42% Fistula-4* Neuropathy-4* GI-4* |
| Holman et al. [71] 2017 | 565 | PC pooled analysis | IOERT | 10–20 | 46 | 95 | 40 months In survivors |
R0 + IORT-72 R1 + IORT-36 R2 + IORT-39 p < 0.0001 |
R0 + IORT-48 R1 + IORT-25 R2 + IORT-17 p < 0.0001 |
NRC: non randomised comparison, RCT: randomised controlled trial, PC: prospective cohort, RC: retrospective cohort, Sx: surgery, R(+): residual after surgery, R0: no residual after surgery, LC: local control, OS: overall survival, NR: not reported,
*
Number of patients,
N.s diff: non-significant difference.